XORTX Therapeutics (XRTX) Net Margin (2022 - 2023)
XORTX Therapeutics (XRTX) posted Net Margin of 140.09% for Q3 2023, down 40.09% on a QoQ basis from 100.0% in Q2 2023, and down 4009.0% year-over-year from 3.58% in Q3 2022.
XORTX Therapeutics (XRTX) Net Margin (2022 - 2023) Analysis & Trends
XORTX Therapeutics' Net Margin history runs 2 years deep, the most recent figure standing at 140.09% for Q3 2023.
- Quarterly Net Margin fell 4009.0% year-over-year to 140.09% in Q3 2023, while the trailing twelve-month figure through Dec 2023 was 198.01% (down 9519.0% YoY) and the FY2023 annual result came in at 79.95%, up 59892.0% from the prior year.
- Net Margin was 140.09% for Q3 2023 at XORTX Therapeutics, down from 100.0% in the prior quarter.
- Across five years, Net Margin topped out at 73.67% in Q4 2022 and bottomed at 140.09% in Q3 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | - |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | 15.02% |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | 34.53% |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | 20.17% |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | 30.33% |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | - |
| 10 | XORTX Therapeutics | 2.91 Bn | 2.91 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2023 | -140.09% |
| Jun 30, 2023 | -100.00% |
| Mar 31, 2023 | -100.00% |
| Dec 31, 2022 | -73.67% |
| Sep 30, 2022 | -100.00% |
| Jun 30, 2022 | -100.00% |
| Mar 31, 2022 | -134.68% |